Thales Launches Sentinel Envelope Plus to Protect Software Against AI-Assisted Reverse Engineering
1.10.2026 08:01:00 CEST | Business Wire | Press Release
Thales, a global leader in advanced technologies, today announced Sentinel Envelope Plus, a new addition to its Sentinel Envelope software protection solution that significantly hardens compiled applications against AI-assisted reverse engineering, automated zero-day vulnerability discovery, and automated exploit generation. Sentinel Envelope Plus applies multiple layers of protection to software applications, without requiring source code changes or any special compilation environments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930063281/en/
AI-assisted tools are making it faster and easier to analyze software for vulnerabilities, reducing the specialist expertise and time traditionally required for reverse engineering. This creates new risks for software vendors, particularly when applications are deployed outside environments they control.
On-premises, embedded and edge devices are at increased risk, as attackers obtain a copy of the application and can analyze it offline, beyond the vendor's security environment. This gives them more opportunity to search for vulnerabilities, proprietary algorithms, business logic and other sensitive elements within the software. For mission-critical systems, the consequences can extend beyond data and intellectual property to operational disruption and lasting damage to the vendor's reputation and customer trust.
“AI is dramatically reducing the time and expertise needed to analyze software for vulnerabilities. Our testing shows that the right software protection can make AI-assisted reverse engineering significantly more difficult and resource-intensive,” said Damien Bullot, Vice President, Software Monetization at Thales. “For software vendors, that additional time matters. It creates a larger window to identify issues, deploy fixes and protect customers, while helping safeguard the intellectual property embedded in their applications.”
Measured results against AI-assisted analysis
Thales conducted a controlled test comparing how an AI agent analyzed the same application before and after protection with Sentinel Envelope Plus. When tasked with analyzing an unprotected application, the agent identified 8 of 10 vulnerabilities. Against the same application protected with Sentinel Envelope Plus, the agent identified none, despite sustained effort and 970 times the token consumption. Even after employing increasingly sophisticated techniques, including generating its own custom analysis tools, the agent ultimately recommended discontinuing the analysis. With no vulnerabilities exposed, there was nothing for an attacker to turn into an exploit.
While the vulnerabilities remain in the code, Sentinel Envelope Plus makes them significantly harder to discover and exploit, giving organizations valuable time to detect and remediate issues. Rather than dropping development work to respond to an internally discovered vulnerability, teams can address issues through their planned release cycles, protecting both their product roadmap and their customers.
How Sentinel Envelope Plus protects software
The new solution extends Thales' existing Sentinel Envelope software protection capabilities, allowing developers to apply advanced protection to selected security-sensitive parts of an application, without changing its source code or requiring a special development environment.
Sentinel Envelope Plus transforms and recompiles selected parts of an application, adding multiple layers of protection against decompilation, tampering and runtime inspection. Developers can choose which parts receive the strongest protection, balancing security with performance.
Sentinel Envelope Plus can also combine software protection with optional licensing capabilities, helping vendors protect proprietary algorithms and business logic while safeguarding the license controls that support their commercial models. As with the code protection itself, these license controls can be added without any source code changes.
Sentinel Envelope Plus is available now as a paid add-on to the Sentinel platform.
To read the full test methodology and results, visit the Thales blog: AI Vulnerability Detection Neutralized. Learn more about Sentinel Envelope Protection Solutions here.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies for the Defence, Aerospace, and Cyber & Digital sectors. Its portfolio of innovative products and services helps address several major challenges: sovereignty, security, sustainability and inclusion.
The Group allocates €4.5 billion per year in Research & Development in key areas, particularly for critical environments, such as Artificial Intelligence, Cybersecurity, Quantum and Cloud technologies. Thales has more than 85,000 employees in 65 countries. In 2025, the Group generated sales of €22.1 billion.
Recent images of Thales and its Defense, Aerospace and Cyber & Digital activities can be found on the Thales Media Library. For any specific requests, please contact the Media Relations team.
PLEASE VISIT
Thales Group
Cybersecurity Products| Thales Group
Cybersecurity Solutions | Thales Group
View source version on businesswire.com: https://www.businesswire.com/news/home/20260930063281/en/
Contacts
PRESS CONTACT
Thales, Media Relations
Security & Cybersecurity
Marion Bonnet
+33 (0) 6 60 38 48 92
marion.bonnet@thalesgroup.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom